Ask AI
ProCE Banner Activity

CE

Innovative Approaches to ATTR-CM: Addressing Health Disparities in African American Populations

Video

Transthyretin cardiac amyloidosis (ATTR-CM) is a progressive and underdiagnosed condition characterized by the deposition of misfolded transthyretin protein in the heart, leading to restrictive cardiomyopathy and heart failure. ATTR-CM disproportionately affects African Americans due to the high prevalence of the Val122Ile mutation, which significantly increases their risk.

Led by chair Dr. Keith C. Ferdinand, alongside experts Dr. Ola O. Akinboboye and Dr. Frederick L. Ruberg, this symposium at the 20th Annual CMHC meeting highlights the critical importance of early detection through imaging, biomarkers, and genetic testing, particularly in African Americans. The experts also review the significant advancements in treatment options, including novel targeted therapies that offer hope for improved disease management. To emphasize the importance of best clinical practices, a patient advocate shares their experience, shedding light on the challenges faced by those living with ATTR-CM.

Pharmacists: maximum of 1.25 contact hours

Dietitians: maximum of 1.25 CPEU(s)

Physicians: maximum of 1.25 AMA PRA Category 1 Credit(s)

Nurses: maximum of 1.25 contact hours

Released: June 22, 2026

Expiration: June 22, 2027

Share

Acknowledgement

Supported by an educational grant from Alnylam Pharmaceuticals, BridgeBio Pharma, Inc, and held in partnership with the Association of Black Cardiologists, Inc. (ABC)

Target Audience

The educational design of this activity addresses the needs of U.S. based healthcare professionals, including internists, family practice physicians, cardiologists, lipidologists, and advanced practice providers.  

Learning Objectives

  • Define the pathophysiology, prevalence, and types of transthyretin cardiac amyloidosis (ATTR-CM)

  • Recognize the disproportionate burden of ATTR-CM in African Americans and the significance of Val122l mutation

  • List screening and diagnostic methods to optimize the early identification of patients with ATTR-CM, including the African American population, based on guidelines

  • Review the different options for the treatment of ATTR-CM, including new and emerging novel targeted agents

  • Select the best treatment for ATTR-CM patients, particularly African Americans, to optimize clinical outcomes

Financial Disclosures

Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Faculty Disclosure

Dr. Ferdinand, faculty for this educational activity, discloses the following:

  • Consultant, Advisor, Speaker: Amgen, Novartis, Boehringer Ingelheim, Medtronic, AstraZeneca 

Dr. Akinboboye, faculty for this educational activity, discloses the following:

  • Consultant, Advisor, Speaker: Alnylam Pharmaceuticals, Astra Zeneca, Bridgebio, Pfizer Inc. 

Dr. Ruberg, faculty for this educational activity, discloses the following:

  • Researcher: BridgeBio Pharm, TriNetX/AstraZeneca, Anumana, Pfizer 

  • Consultant, Advisor, Speaker: eMyosound, Attralus 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Additional Disclosures

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.